- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06079593
GaslEss Macular Hole Surgery (GEM)
GaslEss Macular Hole Surgery (GEM): a Feasibility Study
Macular holes are a hole in the centre of the retina, the light-sensing layer in the back of the eye. They cause a central 'blind spot' in the vision, which can be very disabling for patients. Standard surgery involves injecting a large gas bubble inside the eye. This takes 4-8 weeks to leave the eye. During this time vision is greatly reduced in the eye. This limits patients' ability to drive and work. Gas causes clouding of the natural lens in the eye (cataract). The gas can also raise pressure inside the eye, causing pain and sometimes loss of vision. Patients cannot fly or have certain medicines until the gas absorbs.
Critically, most patients position face down for 50 minutes out of every hour for a week after surgery. This is to float the gas bubble onto the macula. Head positioning is particularly difficult. It very often causes pain in the neck, back, arms and legs. Rarely, blood clots can form in the legs and be life-threatening if they dislodge and travel to the lungs. Head positioning also places a large burden on those caring for the patient.
The gases are 'greenhouse' gases and cause damage to the environment, for about 3,200 years.
This study looks at a new surgical technique for treating macular holes. The new technique aims to make patients' recovery from surgery easier, and safer.
The purpose of this study therefore is to compare two treatments:
- Standard macular hole surgery with gas tamponade
- Novel macular hole surgery without tamponade Gathering feasibility data to inform a future fully powered trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The investigators are testing a new surgical technique, that does not use the gas bubble and face down positioning. Instead, a licensed surgical gel and thin flap of retinal tissue seal the macular hole. Early small studies suggest the new technique is safe and works as well as standard surgery.
The investigators will invite 60 people with macular hole to take part in the study. Half will be randomly allocated to the new technique and half to standard surgery. All participants will return at regular intervals after surgery for review. The investigators will test their vision, examine their eyes, and ask participants to complete questionnaires about their treatment and vision.
The investigators aim to examine if the technique appears safe and works well at closing macular holes. It will also inform if a larger clinical trial is possible.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: George Murphy, MB BCh BAO, FRCOphth
- Phone Number: (+)44 2032991297 ext 31297
- Email: george.murphy4@nhs.net
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Requiring PPV to treat idiopathic (primary) FTMH.
- 18 years or older
- ETDRS BCVA letter score of 1 or better in the study eye
- Able to provide written informed consent
Exclusion Criteria:
General:
- Hypersensitivity to hyaluronate or other components of Healon Pro® viscoelastic
- Any major illness or major surgical procedure within 4 weeks
- Any other condition that, in the opinion of the investigator, would prevent the participant from granting informed consent or complying with the protocol
Study eye
- Previous vitreoretinal surgery, retinopexy, open-globe injury, or endophthalmitis
- Presence of fibrotic retinal proliferation or central epiretinal membrane (within 1 disc diameter of the fovea)
- Aphakia
- Current or former myopia greater than 6 dioptres
- Current or previous posterior uveitis or choroiditis
- Presence of other ocular co-morbidity that, in the opinion of the investigator, is likely to impair BCVA postoperatively or affect FTMH closure
- Current ocular or periocular infection, other than mild or moderate blepharitis
- Lens or media opacity that preclude adequate retinal assessment and imaging
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Gasless Surgery
|
Pars plana vitrectomy to treat full thickness macular hole, with internal limiting membrane flap and ophthalmic viscosurgical device covering
|
Active Comparator: Standard surgery with gas tamponade
|
Pars plana vitrectomy to treat full thickness macular hole, with internal limiting membrane peel, and C2F6 tamponade
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility: Screen failure
Time Frame: 36 months
|
Proportion of those screened who are randomised
|
36 months
|
Feasibility: Recruitment rate
Time Frame: 36 months
|
Recruitment rate (participants per site per month)
|
36 months
|
Feasibility: Participant retention
Time Frame: 6 months
|
Proportion reaching month 6 milestone visit
|
6 months
|
Feasibility: Cross-over
Time Frame: 36 months
|
Proportion converting to standard vitrectomy with gas, due to inability to seal the FTMH, or detection of peripheral retinal breaks
|
36 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy Outcomes: Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA)
Time Frame: 6 months
|
Mean change from baseline
|
6 months
|
Efficacy Outcomes: Surgical success
Time Frame: 3 months
|
Proportion with FTMH closure within 3 months, without further FTMH surgery
|
3 months
|
Efficacy Outcomes: Area under the BCVA versus time curve (ETDRS letter score)
Time Frame: 6 months
|
6 months
|
|
Safety outcomes: Adverse events
Time Frame: 6 months
|
6 months
|
|
Safety outcomes: Intra- and post-operative complications
Time Frame: 6 months
|
6 months
|
|
Safety outcomes: Development or progression of lens opacity
Time Frame: 6 months
|
Within 6 months of vitrectomy (proportion undergoing or listed for cataract surgery and mean change in Lens Opacities Classification System 2 [LOCS2] grading)
|
6 months
|
Patient reported outcomes measures: Participant acceptability of the intervention
Time Frame: 6 months
|
Assessed by the Macular Disease Treatment Satisfaction Questionnaire (MacTSQ; composite score)
|
6 months
|
Patient reported outcomes measures: National Eye Institute 25-Item Visual Function Questionnaire (NEI VFQ25; composite score)
Time Frame: 6 months
|
6 months
|
|
Patient reported outcomes measures: Qualitative analysis
Time Frame: 6 months
|
Analysis of participant feedback
|
6 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Timothy Jackson, PhD, FRCOphth, King's College London & King's College Hospital
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 204994
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Macular Holes
-
Helse Stavanger HFMcGill University; Haukeland University Hospital; Royal Liverpool University... and other collaboratorsNot yet recruitingMacular Holes
-
Oriental Neurosurgery Evidence-Based-Study TeamRecruiting
-
Vienna Institute for Research in Ocular SurgeryCompleted
-
Tianjin Medical UniversityActive, not recruiting
-
Second Affiliated Hospital, School of Medicine,...Unknown
-
Federal University of São PauloUnknown
-
Kyorin UniversityCompleted
-
Fayoum UniversityResearch Institute of Ophthalmology, EgyptRecruiting
-
Minia UniversityRecruiting
-
Faculty Hospital Kralovske VinohradyCharles University, Czech RepublicRecruiting
Clinical Trials on Gasless Macular hole surgery
-
Central Hospital, Nancy, FranceUnknown
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Kyorin UniversityCompletedMacular Hole Surgery
-
The First Affiliated Hospital with Nanjing Medical...CompletedInternal Limiting Membrane Peeling
-
Kyorin UniversityCompleted
-
Seoul Retina Investigator GroupUnknown
-
Xue YingweiActive, not recruiting
-
Minia UniversityUnknownRetinal Detachment | Myopic Macular Degeneration | Macula HoleEgypt
-
The Second Affiliated Hospital of Chongqing Medical...UnknownLaparoscopic SurgeryChina
-
Glostrup University Hospital, CopenhagenThe Danish Medical Research Council; Danish Eye Health SocietyCompletedIdiopathic Macular HoleDenmark